Assessment of the activity and organ damage in antiphospholipid syndrome
https://doi.org/10.14412/1996-7012-2021-4-101-106
Abstract
The review provides a brief description of the clinical and serological markers of antiphospholipid syndrome (APS), risk factors for the development and recurrence of thrombosis in APS. A complete description of the GAPSS and its simplified (corrected) version, adjusted GAPSS (aGAPSS), as well as the DIAPS, is presented. These scales allow one to determine the activity of APS and reflect the range of cumulative and/or irreversible damage due to the disease.
Keywords
antiphospholipid syndrome,
Global Antiphospholipid Syndrome Score (GAPSS),
antiphospholipid syndrome damage index (DIAPS)
Supporting agencies: The investigation has been conducted within scientific topic «Development of methods for personalized therapy of rheumatic diseases with comorbid pathology» (№АААА-А19-119021190151-3).
About the Authors
F. A. Cheldieva
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Department of Rheumatology
34A, Kashirskoe Shosse, Moscow 115522
2/1, Barrikadnaya St., Build. 1, Moscow 125993
T. M. Reshetnyak
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Tatiana Magomedalievna Reshetnyak
Department of Rheumatology
34A, Kashirskoe Shosse, Moscow 115522
2/1, Barrikadnaya St., Build. 1, Moscow 125993
A. M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Department of Rheumatology
34A, Kashirskoe Shosse, Moscow 115522
2/1, Barrikadnaya St., Build. 1, Moscow 125993
References
1. Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (a lecture). Nauchno-prakticheskaya revmatologiya. 2014; 52 (1):56–71. (In Russ.).
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x.
3. Sciascia S, Amigo MC, Roccatello D, Khamashta M. Diagnosing antiphospholipid syndrome: «extra-criteria» manifestations and technical advances. Nat Rev Rheumatol. 2017 Sep;13(9):548-60. doi: 10.1038/nrrheum.2017.124. Epub 2017 Aug 3.
4. Vreede AP, Bockenstedt PL, Knight JS, et al. Antiphospholipid syndrome: an update for clinicians and scientists. Curr Opin Rheumatol. 2017 Sep;29(5):458–66. doi:10.1097/BOR.0000000000000410.
5. Radin M, Ugolini-Lopes MR, Sciascia S, Andrade D. Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. Semin Arthritis Rheum. 2018 Aug; 48(1):117-20. doi: 10.1016/j.semarthrit.2017.12.006. Epub 2018 Jan 5.
6. Rosa RF, Ugolini-Lopes MR, Zeinad-Valim AK, et al. Difficult clinical situations in the antiphospholipid syndrome. Curr Rheumatol Rep. 2015 Apr;17(4):29. doi: 10.1007/s11926-015-0502-7.
7. Alarcon-Segovia D, Pe’rez-Ruiz A, Villa AR. Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun. 2000 Sep;15(2):157-61. doi: 10.1006/jaut.2000.0402.
8. Amigo MC. Prognosis in antiphospholipid syndrome. Rheum Dis Clin North Am. 2001 Aug; 27(3):661–9. doi: 10.1016/s0889-857x(05)70227-1.
9. Tektonidou MG, Varsou N, Kotoulas G, et al. Cognitive deficits in patients with antiphospholipid syndrome: Association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med. 2006 Nov 13;166(20): 2278-84. doi: 10.1001/archinte.166.20.2278.
10. Stojanovich L. Pulmonary manifestations in antiphospholipid syndrome. Autoimmun Rev. 2006 May;5(5):344-8. doi: 10.1016/j.autrev.2006.02.002. Epub 2006 Mar 3.
11. Archimandritis A, Christopoulou V, Tsirantonaki M, et al. Budd-Chiari syndrome in the context of antiphospholipid syndrome: Diagnostic and therapeutic implications. Lupus. 1995 Aug;4(4):329-31. doi: 10.1177/096120339500400420.
12. Lampropoulos CE, Hughes GR. The antiphospholipid (Hughes’) syndrome: Changing the face of neurology. Eur J Intern Med. 2004 Jun;15(3): 147-50. doi: 10.1016/j.ejim.2004.01.017.
13. Muscal E, Brey RL. Neurological manifestations of the antiphospholipid syndrome: Risk assessments and evidence-based medicine. Int J Clin Pract. 2007 Sep;61(9):1561-8. doi: 10.1111/j.1742-1241.2007.01478.x. Epub 2007 Jun 26.
14. Soltesz P, Szekanecz Z, Kiss E, Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev. 2007 Jun;6(6):379-86. doi: 10.1016/j.autrev.2007.01.003. Epub 2007 Jan 31.
15. Tektonidou MG, Malagari K, Vlachoyiannopoulos PG, et al. Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: A prospective study by magnetic resonance imaging. Arthritis Rheum. 2003 Mar;48(3):732-6. doi: 10.1002/art.10835.
16. Vlachoyiannopoulos PG, Kanellopoulos P, Tektonidou M, Moutsopoulos HM. Renal involvement in antiphospholipid syndrome. Nephrol Dial Transplant. 2001;16 Suppl 6:60-2. doi: 10.1093/ndt/16.suppl_6.60.
17. Uthman I, Khamashta M. The abdominal manifestations of the antiphospholipid syndrome. Rheumatology (Oxford). 2007 Nov; 46(11):1641-7. doi: 10.1093/rheumatology/kem158. Epub 2007 Jul 17.
18. Arnason JA, Graziano FM. Adrenal insufficiency in the antiphospholipid antibody syndrome. Semin Arthritis Rheum. 1995 Oct;25(2): 109-16. doi: 10.1016/s0049-0172(95)80024-7.
19. Tektonidou MG, Sotsiou F, Nakopoulou L, et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: Prevalence, clinical associations, and long-term outcome. Arthritis Rheum. 2004 Aug;50(8):2569-79. doi: 10.1002/art.20433.
20. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 Apr;46(4):1019-27. doi: 10.1002/art.10187.
21. Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: A multicenter prospective study of 1000 patients. Ann Rheum Dis. 2009 Sep;68(9):1428-32. doi: 10.1136/ard.2008.093179. Epub 2008 Sep 18.
22. Bucciarelli S, Espinosa G, Cervera R, et al. Mortality in the catastrophic antiphospholipid syndrome: Causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006 Aug;54(8):2568-76. doi: 10.1002/art.22018.
23. Grika EP, Ziakas PD, Zintaras E, et al. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol. 2012 Mar;39(3):516–23. doi: 10.3899/jrheum.110800.
24. Rottem M, Krause I, Fraser A, et al. Autoimmune hemolytic anaemia in the antiphospholipid syndrome. Lupus. 2006; 15(7):473-7. doi: 10.1191/0961203306lu2336oa.
25. Tektonidou MG, Ioannidis JP, Boki KA, et al. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. QJM. 2000 Aug;93(8):523-30. doi: 10.1093/qjmed/93.8.523.
26. Karasawa N, Taniguchi Y, Hidaka T, et al. Antiphospholipid syndrome with autoimmune hemolytic anemia which mimics thrombotic thrombocytopenic purpura. Rinsho Ketsueki. 2010 Apr;51(4):275-80.
27. Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med. 2004;164(1):77-82. doi: 10.1001/archinte.164.1.77.
28. Streiner DL, Norman GR. Health measurement scales: A practical guide to their development and use. 2nd Edition. New York: Oxford University Press Inc; 2003. P. 144–54.
29. Feinstein AR. Clinimetrics. London: Yale University Press; 1987. P. 94–201.
30. Vlachoyiannopoulos PG. Dr. Vlachoyiannopoulos replies. J Rheumatol. 2013 Jan;40 (1):90. doi:10.3899/jrheum.120976.
31. Nasonov EL. Prevention and treatment of antiphospholipid syndrome: current recommendations and prospects. Russkii meditsinskii zhurnal. 2004;(6):377-85. (In Russ).
32. Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013 Aug;52(8):1397-403. doi: 10.1093/rheumatology/kes388. Epub 2013 Jan 12.
33. Sciascia S, Cuadrado MJ, Sanna G, et al. Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort. Arthritis Care Res (Hoboken). 2014 Dec;66 (12): 1915-20. doi: 10.1002/acr.22388.
34. Sciascia S, Sanna G, Murru V, et al. The global anti-phospholipid syndrome score in primary APS. Rheumatology (Oxford). 2015 Jan;54(1): 134-8. doi: 10.1093/rheumatology/keu307. Epub 2014 Aug 13.
35. Oku K, Amengual O, Bohgaki T, et al. An independent validation of the Global AntiPhospholipid Syndrome Score in a Japanese cohort of patients with autoimmune diseases. Lupus. 2015 Jun;24(7):774-5. doi: 10.1177/0961203314561284. Epub 2014 Nov 28.
36. Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012 Feb;64(2):504-12. doi: 10.1002/art.33340.
37. Zuo Y, Li C, Karp DR, Li Z. Clinical and epidemiological correlates of the adjusted global antiphospholipid syndrome score in a large cohort of chinese APS patients. Arthritis Rheumatol. 2015;67 (suppl 10):2183.
38. Amigo MC, Goycochea-Robles MV, Espinosa-Cuervo G, et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus. 2015 Aug;24(9):927-34. doi: 10.1177/0961203315576858. Epub 2015 Mar 11.
39. Ugolini Lopes M, Aguila L, Tonon R, et al. SLICC and DIAPS: Potential indices for damage assessment in primary antiphospholipid syndrome (PAPS). APLA & LACA 2013 14th International Congress on Antiphospholipid Antibodies, 18–21 September 2013, Rio de Janeiro, Brazil.
Review
For citations:
Cheldieva FA, Reshetnyak TM, Lila AM. Assessment of the activity and organ damage in antiphospholipid syndrome. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2021;15(4):101-106. (In Russ.) https://doi.org/10.14412/1996-7012-2021-4-101-106
Views:
658
Email this article 